The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000916347
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
8/07/2026
Date registered
Help: Date registered
24/07/2026
Date last updated
Help: Date last updated
24/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
24/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Hydrogen-rich water supplementation for adults with metabolic syndrome
Scientific title
A double-blind, randomised, placebo-controlled, parallel-group feasibility pilot trial of 12-week hydrogen-rich water supplementation on waist circumference and retention in adults with metabolic syndrome
Additional trial identifiers [1] 317826 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
metabolic syndrome 342752 0
Condition category
Condition code
Metabolic and Endocrine 338887 338887 0 0
Metabolic disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Hydrogen-rich water, generated by dissolving a hydrogen-generating effervescent tablet (releasing ~4 mg H2) in ~250 mL of room-temperature water, consumed on an empty stomach.
Participants self-administer at home after instruction. Tablets are dispensed by GCP-trained research staff at in-person visits, under the oversight of the Chief Investigator and co-investigators.
This is a self-administered oral supplement, not a behavioural or group intervention.
Three tablets/day (~12 mg H2/day total for the active arm), dissolved and consumed three times daily (morning, midday, evening), for 12 consecutive weeks.
Daily consumption occurs at the participant's home. Dispensing and study assessments occur at the Exercise Physiology Clinic Laboratory, Building B, Room B9.33, Southern Cross University Gold Coast Campus.
Adherence:
Returned/unused tablet counts at each visit, logged in an IP accountability log, compared against an adherence target of at least 80%.
Intervention code [1] 334668 0
Treatment: Other
Intervention code [2] 334777 0
Lifestyle
Intervention code [3] 334778 0
Prevention
Description of the comparator or control
A visually and texturally matched placebo effervescent tablet, identical in appearance, taste, and packaging to the active tablet, but produces carbon dioxide instead of hydrogen upon dissolution. Both tablets are manufactured to the same magnesium content (80 mg) to ensure blinding and consistency between study arms.
Participants self-administer at home after instruction; tablets are dispensed by GCP-trained research staff at in-person visits, under oversight of the Chief Investigator and co-investigators.
Three tablets/day, dissolved in ~250 mL room-temperature water, consumed three times daily (morning, midday, evening), for 12 consecutive weeks.
Consumed at the participant's home; dispensed and monitored at the Exercise Physiology Clinic Laboratory, Building B, Room B9.33, SCU Gold Coast Campus.
Returned/unused tablet counts logged at each visit and checked against an adherence target of at least 80%.
Control group
Placebo

Outcomes
Primary outcome [1] 346096 0
Participant retention
Timepoint [1] 346096 0
12 weeks post-randomisation
Primary outcome [2] 346097 0
Waist circumference
Timepoint [2] 346097 0
Baseline (randomisation), 6 weeks post-randomisation, and 12 weeks post-randomisation.
Secondary outcome [1] 464572 0
Fasting blood glucose
Timepoint [1] 464572 0
Baseline (randomisation), 6 weeks post-randomisation, and 12 weeks post-randomisation.
Secondary outcome [2] 464573 0
Fasting insulin
Timepoint [2] 464573 0
Baseline (randomisation), 6 weeks post-randomisation, and 12 weeks post-randomisation.
Secondary outcome [3] 464575 0
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Timepoint [3] 464575 0
Baseline (randomisation), 6 weeks post-randomisation, and 12 weeks post-randomisation.
Secondary outcome [4] 464576 0
Glycated haemoglobin (HbA1c)
Timepoint [4] 464576 0
Baseline (randomisation), 6 weeks post-randomisation, and 12 weeks post-randomisation.
Secondary outcome [5] 464578 0
Total cholesterol
Timepoint [5] 464578 0
Baseline (randomisation), 6 weeks post-randomisation, and 12 weeks post-randomisation.
Secondary outcome [6] 464579 0
Triglycerides
Timepoint [6] 464579 0
Baseline (randomisation), 6 weeks post-randomisation, and 12 weeks post-randomisation.
Secondary outcome [7] 464580 0
Low density lipoprotein cholesterol
Timepoint [7] 464580 0
Baseline (randomisation), 6 weeks post-randomisation, and 12 weeks post-randomisation.
Secondary outcome [8] 464581 0
High density lipoprotein cholesterol
Timepoint [8] 464581 0
Baseline (randomisation), 6 weeks post-randomisation, and 12 weeks post-randomisation.
Secondary outcome [9] 464583 0
High sensitivity C reactive protein
Timepoint [9] 464583 0
Baseline (randomisation), 6 weeks post-randomisation, and 12 weeks post-randomisation.
Secondary outcome [10] 464584 0
Body fat percentage
Timepoint [10] 464584 0
Baseline (randomisation), 6 weeks post-randomisation, and 12 weeks post-randomisation.
Secondary outcome [11] 464585 0
Blood pressure
Timepoint [11] 464585 0
Baseline (randomisation), 6 weeks post-randomisation, and 12 weeks post-randomisation.
Secondary outcome [12] 464587 0
Protocol adherence
Timepoint [12] 464587 0
12 weeks post-randomisation
Secondary outcome [13] 464589 0
Recruitment rate
Timepoint [13] 464589 0
throughout the recruitment period
Secondary outcome [14] 464595 0
Adverse events (Based on prior hydrogen-rich water trials in metabolic syndrome populations, reported adverse events have been rare and mild, predominantly gastrointestinal. Examples: gastrointestinal symptoms (e.g. bloating, heartburn/reflux) assessed via participant self-report on a 5-point Likert scale at each study visit; any other unexpected symptoms captured via open-ended self-report and reviewed by study clinical staff.
Timepoint [14] 464595 0
throughout the 12-week intervention period

Eligibility
Key inclusion criteria
Adults aged 18–65 years
Diagnosed with metabolic syndrome, meeting at least 3 of the following:
Waist circumference at least 102 cm (men) or at least 88 cm (women) (greater than or equal to)
Fasting triglycerides greater than 1.7 mmol/L, or currently receiving treatment for elevated triglycerides
Fasting high-density lipoprotein cholesterol (HDL-C) less than 1.0 mmol/L (men) or less than 1.3 mmol/L (women), or currently receiving treatment for low HDL-C
Fasting glucose at least 5.6 mmol/L, or currently receiving treatment for elevated glucose
Blood pressure at least 130/85 mmHg, or currently receiving antihypertensive treatment (greater than or equal to)
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Pregnancy or breastfeeding
Current smoking
Excessive alcohol consumption, defined as an average intake of more than 10 standard drinks per week, or more than 4 standard drinks on a single occasion on a regular basis
Use of hormonal contraceptives or antioxidant supplements
Use of antibiotics, probiotics, or microbiota regulators within the past 2 months
Active or clinically significant gastrointestinal, autoimmune, or chronic inflammatory conditions (e.g. inflammatory bowel disease, coeliac disease, rheumatoid arthritis, lupus)
History of myocardial infarction, stroke, cancer, liver or kidney disorders, or severe mental health disorders
Positive for HIV infection or chronic dysentery

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sequential allocation of study kit numbers, with the randomisation list linking kit numbers to group allocation held securely by an independent researcher not involved in participant recruitment, assessment, or data analysis. Investigators and study staff have no access to the allocation sequence.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated randomisation sequence, prepared by an independent researcher not involved in participant recruitment or assessment. Participants are allocated in a 1:1 ratio using permuted blocks of four to maintain balance between groups throughout recruitment.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 322367 0
Commercial sector/Industry
Name [1] 322367 0
Natural Wellness Now Health Products Inc
Country [1] 322367 0
Canada
Primary sponsor type
University
Name
Southern Cross University
Address
Country
Australia
Secondary sponsor category [1] 325288 0
Individual
Name [1] 325288 0
Alex Tarnava, CEO of Drink HRW and Natural Wellness Now
Address [1] 325288 0
Country [1] 325288 0
Canada

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320870 0
Southern Cross University Human Research Ethics Committee
Ethics committee address [1] 320870 0
Ethics committee country [1] 320870 0
Australia
Date submitted for ethics approval [1] 320870 0
28/11/2025
Approval date [1] 320870 0
02/04/2026
Ethics approval number [1] 320870 0
2026/045

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151902 0
Dr Luke Del Vecchio
Address 151902 0
Southern Cross University, Southern Cross Drive, Bilinga, QLD 4225, Australia
Country 151902 0
Australia
Phone 151902 0
+61 0408522377
Fax 151902 0
Email 151902 0
Contact person for public queries
Name 151903 0
Luke Del Vecchio
Address 151903 0
Southern Cross University, Southern Cross Drive, Bilinga, QLD 4225, Australia
Country 151903 0
Australia
Phone 151903 0
+61 0408522377
Fax 151903 0
Email 151903 0
Contact person for scientific queries
Name 151904 0
Luke Del Vecchio
Address 151904 0
Southern Cross University, Southern Cross Drive, Bilinga, QLD 4225, Australia
Country 151904 0
Australia
Phone 151904 0
+61 0408522377
Fax 151904 0
Email 151904 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.